ROCKVILLE, Md., Aug. 7, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its second quarter financial results for the three month period ended June 28, 2008. The Company reported a net loss from continuing operations of $3.7 million, or $0.07 per share, compared to a net loss of $10.5 million, or $0.17 per share, for the period ended June 30, 2007. Including results from discontinued operations, Nabi had a net loss of $0.4 million, or $0.01 per share, for the current period compared to a net loss of $4.8 million, or $0.08 per share in the second quarter of 2007.
